QuidelOrtho Corporation/$QDEL
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About QuidelOrtho Corporation
QuidelOrtho Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, which helps clinicians and patients to make decisions across the globe. Geographically, the company has its presence in North America, EMEA, China, and Other countries. It generates the majority of its revenue from North America.
- Ticker
- $QDEL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 6,500
- Headquarters
- San Diego, United States
- Website
- www.quidelortho.com
QDEL Metrics
BasicAdvanced
$908M
-
-$15.40
0.69
-
Price and volume
Market cap
$908M
Beta
0.69
52-week high
$35.58
52-week low
$9.92
Average daily volume
2M
Financial strength
Current ratio
1.386
Quick ratio
0.596
Long term debt to equity
1.514
Total debt to equity
1.733
Interest coverage (TTM)
0.16%
Profitability
EBITDA (TTM)
484.6
Gross margin (TTM)
44.74%
Net profit margin (TTM)
-39.20%
Operating margin (TTM)
1.27%
Effective tax rate (TTM)
-1.79%
Revenue per employee (TTM)
$410,000
Management effectiveness
Return on assets (TTM)
0.35%
Return on equity (TTM)
-45.91%
Valuation
Price to revenue (TTM)
0.337
Price to book
0.51
Price to tangible book (TTM)
-1
Price to free cash flow (TTM)
-4.272
Free cash flow yield (TTM)
-23.41%
Free cash flow per share (TTM)
-3.101
Growth
Revenue change (TTM)
-2.46%
Earnings per share change (TTM)
122.63%
3-year revenue growth (CAGR)
-5.43%
10-year revenue growth (CAGR)
30.51%
3-year earnings per share growth (CAGR)
184.65%
10-year earnings per share growth (CAGR)
44.76%
What the Analysts think about QDEL
Analyst ratings (Buy, Hold, Sell) for QuidelOrtho Corporation stock.
Analyst projections of the future price of QuidelOrtho Corporation stock.
Bulls say / Bears say
In Q2, revenue excluding China grew 6%, with Labs up 9% and Point of Care up 16%. That suggests demand remains healthy across important businesses outside the troubled Chinese market. (QuidelOrtho)
Adjusted EBITDA rose 21% in Q2 and its margin improved by 310 basis points to 20.5%. The company also expects its cost programme to deliver about $50 million in net savings by 2027, supporting the case for further efficiency gains. (QuidelOrtho, SEC)
The LEX acquisition adds an FDA-cleared, rapid point-of-care molecular testing platform, while QuidelOrtho is also advancing its high-sensitivity troponin assay and VITROS 450 system. These launches offer routes to broaden its product range and create future growth, though commercial uptake remains to be proven. (The Motley Fool, QuidelOrtho)
QuidelOrtho cut its 2026 revenue forecast to $2.52–$2.60 billion from $2.70–$2.75 billion and reduced adjusted EPS guidance to $0.65–$0.90 from $1.80–$2.00. It also withdrew free-cash-flow guidance, signalling much weaker near-term expectations and uncertainty over cash generation. (QuidelOrtho)
China remains a significant drag: management reported a 23% constant-currency fall in Q2 China revenue as customers curtailed orders amid uncertainty over proposed IVD pricing rules. Further changes to reimbursement or purchasing could keep demand under pressure. (The Motley Fool, SEC)
Cash generation and leverage leave little room for setbacks: operating cash flow was negative $143.6 million in the first half, and net debt leverage was 4.3 times adjusted EBITDA at Q2. In September, lenders amended the credit agreement to reset leverage and interest-coverage covenants, underscoring the balance-sheet pressure. (SEC, SEC)
Data summarised monthly by Lightyear AI. Last updated on 30 Oct 2026.
QDEL Financial Performance
Revenues and expenses
QDEL Earnings Performance
Company profitability
Upcoming events
No upcoming events
QDEL News
AllArticlesVideos
Funds containing QDEL
AllUSDEURGBP
Fund name | Fund size | $QDEL weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.09% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.09% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.09% |
SPDR MSCI USA Small Cap Value Weighted$USSC | $1.1B | 0.06% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.05% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.